[email protected] +1 646 480 7505 (U.S.) | +44 203 318 2846 (U.K.)

Global Statistics Representing Dry Eye Syndrome Market Scenario

Increasing frequency of dry eye syndrome among the population and growing number of life style disease are some of the factors driving the global dry eye syndrome market. LASIK is becoming highly normal now days and individuals undergoing LASIK surgery will suffer from the dry eye syndrome within the first six months of their treatment. Therefore, it is considered as one of the major driving factors for the growth of the market. Moreover, some of the other factors fueling the growth of the market includes rising the number of research and development and government initiatives. Additionally, another important factor boosting the growth of the market is the launch of new product in the market.  Candorvision introduced the CALMO eye spray, which is one of the first eye spray free of preservatives in Canada.

The global dry eye syndrome was valued around USD 2,200 million in 2017 and is expected to register CAGR of 5.2% in the forecast period.

Intended Audience

  • Pharmaceutical Industry
  • Potential Investors
  • Research and Development Institutes
  • Hospitals and Clinics
  • Government organization

Segmental Insight

The global market of dry eye syndrome is segmented by type and treatment type.

On the basis of type the market is segmented into evaporative dry eye syndrome and aqueous dry eye syndrome. Evaporative eye syndrome is expected to lead dry eye syndrome market. Evaporative eye syndrome is an uncomfortable condition caused by a lack of quality tears.

Based on the treatment type, the market is segmented into nutritional supplements, serum eye drops, lubricant eye drops, and anti-inflammatory drugs.

Regional analysis

Based on the geography, the market is split into four regions such as North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA).

North America is expected to dominate the global dry eye syndrome market owing to increasing prevalence of dry eye syndrome in the U. S.  Furthermore, development of dry eye syndrome drugs and increasing number of approvals for new drugs and devices in the U.S. is driving the growth of the dry eye syndrome market. According to the American Journal of ophthalmology, around 6.8% of the U.S. adult population was projected to have diagnosed dry eye syndrome disease. Prevalence raised with the age of 18-34 years that is 2.7% and was higher in women (8.8%) then in men (4.5%).

Europe is expected to be second dominating region owing to increasing technological developments, government support, and various reimbursement policies.  However, adoption of contact lens is supporting the growth of the market. Furthermore, growing environmental pollution leading to allergy and dry eyes. Increasing incidences of vitamin A deficiency causing different eye diseases is supporting the growth of the market.

Asia Pacific is expected to grow at the significant rate due to the increasing number of patients with dry eye disease. Moreover, there is growing per capita healthcare expenditure and rising investment of key players in this market are some of the other factors boosting the market in APAC. In India increasing the prevalence of dry eye syndrome in women owing to hormonal changes during pregnancy and after menopause is propelling growth of the dry eye syndrome market.

LAMEA is exhibiting steady growth for the market due to less advanced technology. On the other hand, the Middle East & Africa holds the least share in the market due to the poor healthcare infrastructure, limited availability of funds, low spending power in Africa region. However, the region is expecting a sound growth due to many untapped opportunities in this region.

Key findings

  • In May 2018, Teva Canada Limited launched Teva-Cyclosporine ophthalmic emulsion. First generic version of Restasis (cyclosporine) in Canada.
  • In April 2018, Allergan launched TrueTear. Temporarily rise tear production during neurostimulation in adult dry eye syndrome patients.
  • In November 2017, Santen Pharmaceutical Co. Ltd. received the import drug license for Diquas Ophthalmic Solution for the treatment of dry eye syndrome in China.

Key Players

Some of the major key players in dry eye syndrome market include Allergan, Alcon, Santen Pharmaceutical Co. Ltd., Shire/SAR code Bioscience, Otsuka Holdings, Can-Fite Biopharma, Novartis, and Eyegate Pharma.

Dry Eye Syndrome Market Segmentation

By Type

  • Evaporative Dry eye syndrome
  • Aqueous Dry eye syndrome

By Treatment Type:

  • Nutritional Supplements
  • Serum Eye Drops
  • Lubricant Eye Drops
    • Oily Tear Eye Drops
    • Ointments
    • Preservative-Free drops
  • Anti-inflammatory drugs Segments
    • Tetracyclines
    • Corticosteroids

   By Regions

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA

Why to buy this report right now?

  • Historical inferences, findings & analysis of the market from 2016 to 2018
  • Projections and performance forecast analysis for future from 2019 to 2026
  • Production and consumption point of view (POV) analysis
  • Market drivers, constraints and growth opportunity analysis to determine market dynamics covering industry, regulatory, breakthrough innovations, technological & pricing trends.
  • Comprehensive competitive landscape mapping with recent development covering market leadership, competency, sustainability and future prospects


Request For Free Sample
Choose license Type

Buy Chapters or Sections

Avail customized purchase option to meet your exact research needs:

1)Buy sections of the report
2)Buy country level report
3)Request for historical data

Request a Free Sample   Special Pricing
Related Reports